Fluconazole to Prevent Systemic Fungal Infections in Infants: Reviewing the Evidence
IN NEONATOLOGY, EVIDENCE-BASED practice (EBP) relies on well-designed, adequately powered trials to guide practitioners. Several large randomized controlled trials (RCTs) have been conducted to explore the use of fluconazole for fungal prophylaxis in premature infants. Despite the findings of these studies, practice varies among units. In a recent survey of members of the American Academy of Pediatrics (AAP), 34 percent of clinicians indicated that they have used antifungal prophylaxis and only 11 percent of clinicians indicated that a written protocol was in place in their NICU. Intravenous (IV) fluconazole (66 percent), oral nystatin (59 percent), and IV amphotericin (21 percent) were the three most commonly used agents among the respondents.1
Document Type: Research Article
Publication date: September 1, 2010
- Neonatal Network®, established in April 1981, is a peer-reviewed journal dedicated to assisting neonatal nurses and related health care professionals remain current in their fields. Neonatal Network® acts as a vehicle for the exchange of information by providing up-to-date, relevant articles in the areas of evidence-based clinical practice, research, and education.
Neonatal Network® is issued six times a year; January/February, March/April, May/June, July/August, September/October, and November/December. With a circulation of 10,000, Neonatal Network® goes to more than 1,000 recognized Level II and Level III neonatal intensive care units in the United States.
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Academy of Neonatal Nursing Membership Information
- Academy of Neonatal Nursing Free Access to Journal Contents Online
- Request a Sample Issue
- ingentaconnect is not responsible for the content or availability of external websites